Bristol/Sanofi Push Plavix To Exhaust Generic Supply; Levels Remain Unclear
Executive Summary
Bristol-Myers Squibb and Plavix marketing partner Sanofi-Aventis have ramped up promotional efforts for the blockbuster antithrombotic in an effort to exhaust outstanding generic supply as quickly as possible
You may also be interested in...
Combo Lipid-Lowering Drugs Will Help Drive Cholesterol Market In 2007 – IMS
Patent losses this year for blockbuster lipid-lowering agents including Merck's Zocor (simvastatin) and Bristol-Myers Squibb's Pravachol (pravastatin) will cause a six percentage point drop in growth in the class in 2007, but the advent of combination therapies are expected to help offset the negative impact, IMS Health projects
Combo Lipid-Lowering Drugs Will Help Drive Cholesterol Market In 2007 – IMS
Patent losses this year for blockbuster lipid-lowering agents including Merck's Zocor (simvastatin) and Bristol-Myers Squibb's Pravachol (pravastatin) will cause a six percentage point drop in growth in the class in 2007, but the advent of combination therapies are expected to help offset the negative impact, IMS Health projects
Bristol Is Not For Sale, CEO Says; Plavix Woes Partly Offset By Other Products
Bristol-Myers Squibb Interim CEO Jim Cornelius is becoming more confident the company can operate as an independent entity going forward